These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26134970)

  • 1. GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines.
    Durbas M; Horwacik I; Boratyn E; Kamycka E; Rokita H
    Int J Oncol; 2015 Sep; 47(3):1143-59. PubMed ID: 26134970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells.
    Horwacik I; Durbas M; Boratyn E; Węgrzyn P; Rokita H
    Cancer Lett; 2013 Dec; 341(2):248-64. PubMed ID: 23962557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin A receptor antagonism enhances inhibitory effects of anti-ganglioside GD2 monoclonal antibody on invasiveness and viability of human osteosarcoma cells.
    Liu B; Wu Y; Zhou Y; Peng D
    PLoS One; 2014; 9(4):e93576. PubMed ID: 24727660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
    Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
    Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H; Jin X; Zhang Z; Xing Y; Kong X
    Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of genes involved in response to doxorubicin and a GD2 ganglioside-specific 14G2a monoclonal antibody in IMR-32 human neuroblastoma cells.
    Horwacik I; Durbas M; Boratyn E; Sawicka A; Węgrzyn P; Krzanik S; Górka A; Drożniak J; Augustyniak E; Kowalczyk A; Rokita H
    Acta Biochim Pol; 2015; 62(3):423-33. PubMed ID: 26284262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo.
    Segerström L; Baryawno N; Sveinbjörnsson B; Wickström M; Elfman L; Kogner P; Johnsen JI
    Int J Cancer; 2011 Dec; 129(12):2958-65. PubMed ID: 21717457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma.
    Agnihotri S; Gugel I; Remke M; Bornemann A; Pantazis G; Mack SC; Shih D; Singh SK; Sabha N; Taylor MD; Tatagiba M; Zadeh G; Krischek B
    J Neurosurg; 2014 Dec; 121(6):1434-45. PubMed ID: 25245477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dual PI3K/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talk.
    Seitz C; Hugle M; Cristofanon S; Tchoghandjian A; Fulda S
    Int J Cancer; 2013 Jun; 132(11):2682-93. PubMed ID: 23151917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vertical inhibition of PI3K/Akt/mTOR signaling demonstrates in vitro and in vivo anti-fibrotic activity.
    Liang M; Lv J; Chu H; Wang J; Chen X; Zhu X; Xue Y; Guan M; Zou H
    J Dermatol Sci; 2014 Nov; 76(2):104-11. PubMed ID: 25258031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade.
    Mitra A; Raychaudhuri SK; Raychaudhuri SP
    Cytokine; 2012 Oct; 60(1):38-42. PubMed ID: 22840496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
    Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
    Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of PI3K inhibition in human neuroblastoma using multiplex luminex bead immunoassay: a targeted approach for pathway analysis.
    Lang WH; Sandoval JA
    J Biomol Screen; 2014 Oct; 19(9):1235-45. PubMed ID: 25092063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
    Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
    Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
    Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Honokiol induces autophagy of neuroblastoma cells through activating the PI3K/Akt/mTOR and endoplasmic reticular stress/ERK1/2 signaling pathways and suppressing cell migration.
    Yeh PS; Wang W; Chang YA; Lin CJ; Wang JJ; Chen RM
    Cancer Lett; 2016 Jan; 370(1):66-77. PubMed ID: 26454217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma.
    Fulda S
    Curr Cancer Drug Targets; 2009 Sep; 9(6):729-37. PubMed ID: 19754357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.